We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK’s Benlysta Approved to Treat Active Lupus Nephritis
GSK’s Benlysta Approved to Treat Active Lupus Nephritis
GlaxoSmithKline has received FDA approval for Benlysta (belimumab) to treat active lupus nephritis, a serious inflammation of the kidneys that appears in about four in 10 patients with the most common form of lupus. The inflammation can lead to end-stage kidney disease, requiring dialysis or a kidney transplant.